Of all 481 intermediate-risk prostate cancer patients, BCR was experienced by 51 of 328 (16%) patients with an interval from biopsy to RP ≤3 months and by 18 of 153 (12%) patients with an interval from biopsy to RP >3 and ≤6 months. The gene discussed is BCR; the disease is prostate carcinoma.